BCM
LYEL icon

Bridgeway Capital Management’s Lyell Immunopharma LYEL Stock Holding History

Bridgeway Capital Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$361K Hold
18,000
– – 0.01% 890
2025
Q4 		$554K Hold
18,000
– – 0.01% 801
2025
Q3 		$292K Hold
18,000
– – 0.01% 933
2025
Q2 		$159K Buy
+18,000
New +$164K ﹤0.01% 1006

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bridgeway Capital Management's LYEL Position: Q1 2026 in Review

Bridgeway Capital Management held its Lyell Immunopharma (LYEL) position steady in Q1 2026 at 18,000 shares worth $361K. The position accounts for 0.01% of the portfolio, ranked #890.

Bridgeway Capital Management first reported a position in LYEL in Q2 2025 and has held it in 4 quarters since. The position peaked at $554K in Q4 2025. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Bridgeway Capital Management held 18,000 shares of Lyell Immunopharma worth $361K as of Q1 2026.
  • Bridgeway Capital Management left its Lyell Immunopharma share count unchanged in Q1 2026.
  • Lyell Immunopharma made up 0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #890 holding.
  • Bridgeway Capital Management first reported a position in Lyell Immunopharma in Q2 2025 and has held it in 4 quarters since.
  • Bridgeway Capital Management's Lyell Immunopharma position peaked at $554K in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.